secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001641172-25-025273
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics closes $6.9M public offering with full over-allotment exercise
--------------------------------------------------------------------------------

- Gross proceeds of $6.9M from 1,922,764 common stock units and 1,528,000 pre-funded warrant units.
- Each unit priced at $2.00 (common) or $1.999 (pre-funded); Series I warrants exercisable at $2.00 for 5 years.
- Underwriters exercised 450,000-unit over-allotment option in full; Ladenburg Thalmann sole book-runner.
- Proceeds for working capital, pre-clinical studies, and clinical trial preparation.
- Directors and executive officers subject to 90-day lock-up agreements post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225025273/0001641172-25-025273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225025273/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer